

**TABLE 3.****RECTAL CANCER MEASURE**

THE MEASURE BELOW WAS DEVELOPED AND SPECIFIED BY ASCO AND NCCN.

**Postoperative adjuvant chemotherapy is considered or administered within 9 months (270 days) of diagnosis for patients under the age 80 years with AJCC stage II or stage III rectal cancer.**

Application	Type	Denominator	Numerator
Hospital or systems-level performance	Accountability	<ul style="list-style-type: none"> <li>• Age 18-79 at time of diagnosis</li> <li>• Known or assumed to be first or only cancer diagnosis</li> <li>• Primary tumors of the rectum</li> <li>• Epithelial malignancy only</li> <li>• AJCC clinical or pathologic AJCC Stage II or Stage III</li> <li>• Known to be alive within 9 months (270 days) of diagnosis</li> </ul>	Consideration or administration of postoperative adjuvant chemotherapy initiated within 9 months (270 days) of date of diagnosis

**Evidence**

**NICCQ Measure: CO-2B3a.** <http://www.jco.org/cgi/content/abstract/24/4/626>

**NCCN Guideline Recommendations v2.2006**

**REC-3/REC-B:** cT3, N0 or T any, N1-2 should receive neoadjuvant concurrent chemo/RT OR adjuvant chemotherapy.

OR cT4 and/or locally unresectable should receive neoadjuvant concurrent chemo/RT combination.

Postoperative therapy is indicated in all patients who receive preoperative therapy, regardless of the surgical pathology results.